Zenas BioPharma, Inc. Common Stock
ZBIOZenas BioPharma, Inc. (ZBIO) is a biopharmaceutical company focused on developing innovative therapies for cancer and immune-related diseases. The company aims to advance novel treatments by leveraging cutting-edge science and targeted approaches to address unmet medical needs in oncology and immunology.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 2, 2020 | $0.00 | 2019-12-24 | 2019-12-26 |
| October 2, 2019 | $0.02 | 2019-09-25 | 2019-09-26 |
| July 2, 2019 | $0.02 | 2019-06-25 | 2019-06-26 |
| March 27, 2019 | $0.01 | 2019-03-20 | 2019-03-21 |
| January 3, 2019 | $0.01 | 2018-12-26 | 2018-12-27 |
Dividends Summary
- Consistent Payer: Zenas BioPharma, Inc. Common Stock has rewarded shareholders with 5 dividend payments over the past 1 years.
- Total Returned Value: Investors who held ZBIO shares during this period received a total of $0.05 per share in dividend income.
- Latest Payout: The most recent dividend of $0.00/share was paid 2389 days ago, on January 2, 2020.
- Yield & Schedule: ZBIO currently pays dividends quarterly with an annual yield of 0.16%.
- Dividend Growth: Since 2019, the dividend payout has decreased by 60.7%, from $0.01 to $0.00.
Company News
Zenas BioPharma announced that obexelimab met its primary and all key secondary endpoints in the Phase 3 INDIGO trial for Immunoglobulin G4-Related Disease (IgG4-RD). The drug demonstrated a 56% reduction in flare risk, 65% reduction in glucocorticoid use, and favorable safety profile comparable to placebo. A Biologics License Application (BLA) w...
Zenas BioPharma reported Q1 2026 financial results with cash position of $718.5M and extended runway through Q2 2029. The company advanced obexelimab toward FDA/EMA submissions for IgG4-RD treatment, completed enrollment in the Phase 2 SunStone SLE trial with results expected Q4 2026, initiated Phase 1 testing of oral IL-17 inhibitor ZB021, and c...
InnoCare Pharma achieved its first annual profit of 644 million yuan in 2025, two years ahead of schedule, driven by dual revenue engines of licensing deals and product sales. The company's main drug Orelabrutinib continues strong momentum with expanded indications, while new products like Tafasitamab and pipeline asset Mesutoclax advance develop...
Zenas BioPharma priced a concurrent public offering of $200 million in 2.50% convertible senior notes due 2032 and 5 million shares of common stock at $20 per share, with estimated net proceeds of $287.5 million. The company plans to use proceeds to support the U.S. commercial launch of obexelimab for IgG4-RD treatment and advance its development...
ENAVATE Sciences increased its stake in Zenas BioPharma by 157,800 shares worth $5.19 million, making it the fund's largest holding at 28.08% of AUM. The position grew to $142.30 million by quarter-end, driven by both the purchase and significant stock price appreciation (up 167% year-over-year). The real focus should be on Zenas' pipeline, parti...
